Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

C. Scoccianti, G. Martel, M. Olivier, P. Hainaut, A. Vesin, E. Brambilla, J.-F. Timsit, C. Brambilla, J.K. Field, L. Tavecchio, Y. Martinet, E. Thunnissen, P. Snijders, G. Sozzi, A. Risch, S. Elborn, L.M. Montuenga, K. O'Byrne, D.J. Harrison, J. Niklinski

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR genes. The series included 11 never-smokers, 86 former smokers, 152 current smokers and one patient without informed smoking status. There were 110 squamous cell carcinomas (SCCs), 133 adenocarcinomas (ADCs) and seven large cell carcinomas or mixed histologies. Expression of p53 was analysed by immunohistochemistry. DNA was extracted from frozen tumour tissues. TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p
Original languageEnglish
Pages (from-to)177-184
Number of pages8
JournalEuropean Respiratory Journal
Volume40
Issue number1
DOIs
Publication statusPublished - 01 Jul 2012

Fingerprint Dive into the research topics of 'Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort'. Together they form a unique fingerprint.

  • Cite this

    Scoccianti, C., Martel, G., Olivier, M., Hainaut, P., Vesin, A., Brambilla, E., Timsit, J-F., Brambilla, C., Field, J. K., Tavecchio, L., Martinet, Y., Thunnissen, E., Snijders, P., Sozzi, G., Risch, A., Elborn, S., Montuenga, L. M., O'Byrne, K., Harrison, D. J., & Niklinski, J. (2012). Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort. European Respiratory Journal, 40(1), 177-184. https://doi.org/10.1183/09031936.00097311